Drugs / Umbilical Cord Blood-derived Natural Killer Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03579927 | Oct 2019 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Blood-derived Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03579927 ↗ |
| Modality | Cell therapy | “CAR-NK cells” NCT03579927 ↗ |
| Route | Intravenous | “CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5” NCT03579927 ↗ |
| Target | CD19 | “CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells” NCT03579927 ↗ |